A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma

Trial Profile

A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs ERY-ASP (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 10 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
    • 13 Feb 2017 Planned number of patients changed from 12 to 24.
    • 13 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top